Evidence map›Paper›PMID 40665874›Full record

ArticleCancer communications (London, England)2025

Targeting SPHK1 in macrophages remodels the tumor microenvironment and enhances anti-PD-1 immunotherapy efficacy in colorectal cancer liver metastasis.

Yizhi Zhan, Jinsong Xu, Zhanqiao Zhang, Yating Hu, Yongsheng Li, Junying Qian, Yunyan Ling, Dehua Wu, Haijun Deng, Guoxin Li and 2 more

Abstract read
In one paragraph

Article in Cancer communications (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yizhi ZhanDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.ORCID 0000-0002-5079-6129
Jinsong XuDepartment of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Zhanqiao ZhangDepartment of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Yating HuDepartment of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Yongsheng LiDepartment of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Junying QianDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Yunyan LingDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Dehua WuDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Haijun DengDepartment of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Guoxin LiDepartment of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Zhiyong ShenDepartment of General Surgery, Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Yuan FangDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.

Funding

China Postdoctoral Science Foundation 2023M731542National Natural Science Foundation of China 82103595National Natural Science Foundation of China 82403009Outstanding Youth Cultivation Program of Nanfang Hospital of Southern Medical University 2020J010Science and Technology Program of Guangzhou 2025A04J4189the Guangdong Basic and Applied Basic Research Foundation 2022A1515111142the Guangdong Basic and Applied Basic Research Foundation 2023A1515010980the Guangdong Basic and Applied Basic Research Foundation 2023A1515011789the Guangdong Basic and Applied Basic Research Foundation 2025A1515011911
6 · The paper itself

Abstract

backgroundColorectal cancer liver metastasis (CRLM) is characterized by an immunosuppressive microenvironment and a blunted response to immunotherapy. Notably, tumor-associated macrophages (TAMs) play a critical role in modulating immune responses and exhibit significant heterogeneity in CRLM. Sphingosine kinase 1 (SPHK1) serves as a pivotal kinase in maintaining the balance between ceramide and sphingosine-1-phosphate (S1P) levels. However, the effects of SPHK1 within TAMs on tumor immune evasion during CRLM remain elusive. This study aimed at investigating the role of TAM-intrinsic SPHK1 in tumor immunosuppressive microenvironment in CRLM.

methodsSPHK1 expression levels in TAMs were estimated by immunofluorescence and bioinformatics analysis. Several animal models were established to elucidate the role of SPHK1 in tumor immunity reprogramming in vivo. Flow cytometry, cytokine assay, and transwell assay were conducted to investigate the effects of SPHK1 in TAMs in cell-cell communication in vitro. RNA-sequencing, Western blotting, and quantitative real-time polymerase chain reaction were used to explore the molecular mechanism by which SPHK1 activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in TAMs.

resultsWe found that SPHK1 was mainly expressed in TAMs and identified SPHK1

conclusionsOur findings highlighted the role of SPHK1 of TAMs in facilitating CRLM by promoting CD8

Indexed as

Colorectal NeoplasmsImmune Checkpoint InhibitorsLiver NeoplasmsPhosphotransferases (Alcohol Group Acceptor)Programmed Cell Death 1 ReceptorTumor-Associated MacrophagesTumor MicroenvironmentAnimalsCell Line, TumorFemaleHumansImmunotherapyMaleMiceSphingosine KinaseImmune Checkpoint InhibitorsPDCD1 protein, humanPhosphotransferases (Alcohol Group Acceptor)Programmed Cell Death 1 ReceptorSphingosine KinaseCD8+ T cellscolorectal cancer liver metastasisimmunotherapySPHK1tumor‐associated macrophages

Identifiers

PMID40665874
PMCPMC12531427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.